First-in-class drug development remains low

While antibiotics boast a vast pipeline, with 741 products currently in development, the majority is dominated by generics, as weak financial incentives and high failure rates have discouraged innovation, says GBI Research


(Photo Courtesy:

According to the company's latest report, financial incentives have been lacking over the past few decades.

Healthcare organizations, such as the UK's National Health Service, remain unwilling to prescribe newly-diagnosed, premium products, due to their inferior cost effectiveness to generics and a desire to limit their use to prevent growth in antibiotic resistance.

Furthermore, antibiotic development is notoriously difficult, with high failure rates.

This is reflected in the fact that only 12 new drugs have been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) since 2000, with just four of these products boasting first-in-class status.

Ms Katie Noon, analyst, GBI Research, said, "In response to growing concerns over the lack of new antibiotics, the FDA passed the 2011 Generating Antibiotics Incentives Now Act to help boost development in the field. This was followed by Europe's similarly-aimed COMBACTE project initiated in January 2013."


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email